- ￥1800
- BHcell（博辉生物）
- H-C274
- 2026年01月15日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
T.T(TT)/T.T(TT)细胞系/T.T(TT)细胞株/T.T(TT)人甲状腺癌细胞
Cell line name TT
Synonyms MTC-TT
Accession CVCL_1774
Resource Identification Initiative To cite this cell line use: TT (RRID:CVCL_1774)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~83 hours (ATCC=CRL-1803).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Cell type: Parafollicular cell; CL=CL_0000570.
Sequence variations
Mutation; HGNC; 9967; RET; Simple; p.Cys634Trp (c.1902C>G); ClinVar=VCV000013918; Zygosity=Heterozygous (PubMed=7736432; PubMed=30737244; Cosmic-CLP=930299; DepMap=ACH-001321).
Mutation; HGNC; 11602; TBX3; Simple; p.Trp197Ter (c.591G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP=930299; DepMap=ACH-001321).
PubMed=2519210
Kameya T., Kadoya K., Iguchi H.
Characterization and calcitonin secretion of a human well differentiated C-cell tumor cell line.
Hum. Cell 2:231-237(1989)
PubMed=1516062
Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.
Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.
Cancer Res. 52:5061-5064(1992)
DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York; USA (1994)
PubMed=7736432; DOI=10.1016/0165-4608(94)00185-E
Cooley L.D., Elder F.F.B., Knuth A., Gagel R.F.
Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines.
Cancer Genet. Cytogenet. 80:138-149(1995)
PubMed=7864888; DOI=10.1006/bbrc.1995.1287
Carlomagno F., Salvatore D., Santoro M.M., de Franciscis V., Quadro L., Panariello L., Colantuoni V., Fusco A.
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.
Biochem. Biophys. Res. Commun. 207:1022-1028(1995)
PubMed=9046062; DOI=10.14670/HH-12.283
Zabel M., Grzeszkowiak J.
Characterisation of thyroid medullary carcinoma TT cell line.
Histol. Histopathol. 12:283-289(1997)
PubMed=11751535; DOI=10.1093/clinchem/48.1.25
Zammatteo N., Lockman L., Brasseur F., De Plaen E., Lurquin C., Lobert P.-E., Hamels S., Boon T., Remacle J.
DNA microarray to monitor the expression of MAGE-A genes.
Clin. Chem. 48:25-34(2002)
PubMed=19897677; DOI=10.1210/jc.2009-1485; PMCID=PMC2805480
Zhu W., Hai T., Ye L., Cote G.J.
Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on Ret proto-oncogene activity.
J. Clin. Endocrinol. Metab. 95:439-444(2010)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由博辉生物科技（广州）有限公司提供； *发表【英文论文】请标注：From Bohui Biological Technology (Guangzhou) Co., Ltd.
【求助】-344 T allele and -344 CT/TT genotype是 什么意思
feiyu1024 在看一篇文献 看到-344 T allele and -344 CT/TT genotype 请问 这几个是什么区别 请高人指点 Fasta921 gene polymorphism 个人觉得：某对等位基因344位所对应的碱基为CT或TT。344 CT/TT genotype 作为载体包含T allele 。 feiyu1024 在文章中 好像二者
edwardellen 求助！！！ 本人菜鸟，最近开始接触凋亡相关信号，在HepG-2中做实验，有一点很困惑，HepG-2中的p53是野生型的还是突变型的？还是两者都存在？查了一些资料，有些文章之间表达的意思模凌两可。困惑啊！ 哪位好心的达人能给我一个确定的答案呢？ 另外，是否有做p53相关的牛人能告诉我P53在哪些实验用肿瘤细胞系中是野生型的，在哪些是突变型的？ 谢谢！谢谢！谢谢！ doctormy
血清中99.95%以上的T4与蛋白结合，其中80%～90%与球蛋白结合称为甲状腺素结合球蛋白(简称TBG)。TT4是指T4与蛋白结合的总量，受TBG等结合蛋白量和结合力变化的影响，TBG又受妊娠、雌激素、病毒性肝炎等因素影响而升高，受雄激素、低蛋白血症(严重肝病、肾病综合征)、泼尼松等影响而下降，在临床上必需注意。 血清TT4测定方法有放射
技术资料
